Pharmaceutical Company Commends 2017 Advanced

Release time:


On the afternoon of January 29, Jianfeng Pharmaceutical Company held a 2017 annual summary commendation meeting to summarize the work of the past year, commend the outstanding collectives and individuals of the pharmaceutical company in 2017, and put forward the work ideas for the new year.

2017 is an important year for comprehensively deepening reforms. The pharmaceutical industry is in a period of policy adjustment and turbulence. National pharmaceutical policies are frequent, especially the continuous advancement of new medical reform policies, and the rapid implementation of drug regulatory policies, which have brought to the pharmaceutical industry. New opportunities and challenges. In the face of the complex and changeable industrial situation and market environment, the pharmaceutical company closely revolves around the business objectives set at the beginning of the year, seizes the opportunity of industry integration and market expansion, carries out all kinds of work in a down-to-earth manner, and achieves good results.

At the meeting, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, on behalf of the management team of the pharmaceutical company, made a work report entitled "comply with new policies, meet new challenges, gather new forces to achieve new leaps". He started from the completion of economic indicators, scientific and technological innovation achievements, brand promotion of enterprises and products, enterprise expansion, completion and use of technological transformation projects, strengthening of internal management and refinement of marketing work, the party-mass work and other aspects reviewed the main work in 2017 and analyzed the industry situation and policies in 2018. He pointed out that 2018 is a very critical year for the pharmaceutical industry, and the newly revised Drug Administration Law will be implemented. Drug registration management measures, drug technology transfer management measures, drug marketing license holder system, GMP and GSP certification systems will be revised accordingly. With the continuous introduction of policies, the entire industry will undergo tremendous changes. Pharmaceutical companies will proceed from the actual situation of the company, fully tap their own advantages, take innovation and standardization as the main line, and steadily advance various tasks. At the meeting, he made arrangements for the key work in 2018.

Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, Qin Xuping, chairman of the trade union of the group company, and leaders of the pharmaceutical company presented awards to the advanced collectives and individuals of the pharmaceutical company in 2017. He Songqin, Han Ying and Zhao Xiuju spoke at the meeting on behalf of advanced collectives, outstanding scientific and technological workers and outstanding salesmen in 2017.

Chairman Jiang Xiaomeng, on behalf of the group company, congratulated the advanced collectives and individuals who were commended, affirmed the efforts made by all employees of the pharmaceutical company in the past year, and put forward requirements for the work of the pharmaceutical company in 2018. He asked pharmaceutical companies to increase talent training; speed up consistency evaluation and new drug research and development; establish the concept of marketing first responsibility, innovate marketing models; expand the scale of retail business; establish and improve internal assessment and incentive mechanisms to mobilize all levels The subjective initiative of personnel.

At the meeting, on behalf of the pharmaceutical company, golden dragon signed a new year's economic target responsibility system with the heads of subordinate enterprises and departments.